SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2357-2365

  Han, Lin ^a   Liang, Xiao Hua ^b   Chen, Li Xin ^a   Bao, Shi Min ^a   Yan, Zhi Qiang ^a  

^a Chinese Academy of Sciences   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Brain metastasis; Epigenetics; Non small cell lung cancer; RNAi screening; SIRT1

Indexed keywords

HISTONE DEMETHYLASE; KDM5B PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TUMOR MARKER;

ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; ENZYMOLOGY; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METASTASIS; NON-SMALL CELL LUNG CANCER; PATHOLOGY; RNA INTERFERENCE; RNAI SCREENING; SIRT1; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION; WOUND HEALING;

BRAIN METASTASIS; EPIGENETICS; NON-SMALL CELL LUNG CANCER; RNAI SCREENING; SIRT1;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; RNA INTERFERENCE; SIRTUIN 1; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; WOUND HEALING;

EID: 84887050198     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma:primary tumor size, cell type, and lymph node metastases. Radiology 2007;242:882-888.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-2872.
3. Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 2008;71:79-86.
4. McHaffie DR, Chabot P, Dagnault A, Suh JH, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, Schultz C, Werner-Wasik M, Gaspar LE, Brachman D, Mody T, Mehta MP. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of
5. Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011;21:107-112.
6. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013;31:895-902.
7. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390):a phase 4 study. Lancet Oncol 2010;11:733-740.
8. Yan DF, Yan SX, Yang JS, Wang YX, Sun XL, Liao XB, Liu JQ. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy:two case reports and review of the literature. BMC Cancer 2010;10:49.
9. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-5261.
10. Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis. Cancer Res 2013;73:5053-65.
11. Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H. alphav-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer 2013;133:2362-71.
12. Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 2013;3:26-33.
13. Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK, Kim SH, Kim IS, Hong JT, Sung JH, Son BC, Lee SW. E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. J Neurooncol 2012;109:219-227.
14. Pang X, Min J, Liu L, Liu Y, Ma N, Zhang H. S100B protein as a possible participant in the brain metastasis of NSCLC. Med Oncol 2012;29:2626-2632.
15. Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol 2010;3:775-781.
16. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S, Krichevsky AM. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 2012;14:689-700.
17. Jia W, Martin TA, Zhang G, Jiang WG. Junctional adhesion molecules in cerebral endothelial tight junction and brain metastasis. Anticancer Res 2013;33:2353-2359.
18. Wang Y, Shang Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res 2013;319:160-169.
19. Li Q, Chen H. Silencing of Wnt5a during colon cancer metastasis involves histone modifications. Epigenetics 2012;7:551-558.
20. Carmona FJ, Villanueva A, Vidal A, Munoz C, Puertas S, Penin RM, Goma M, Lujambio A, Piulats JM, Mesia R, Sanchez-Cespedes M, Manos M, Condom E, Eccles SA, Esteller M. Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol 2012;228:230-240.
21. Wu Y, Li J, Sun CY, Zhou Y, Zhao YF, Zhang SJ. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells. Neoplasma 2012;59:326-332.
22. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-589.
23. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J, Brabletz T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011;30:770-782.
24. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vagbo CB, Shi Y, Wang WL, Song SH, Lu Z, Bosmans RP, Dai Q, Hao YJ, Yang X, Zhao WM, Tong WM, Wang XJ, Bogdan F, Furu K, Fu Y, Jia G, Zhao X, Liu J, Krokan HE, Klungland A, Yang YG, He C. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell 2013;49:18-29.
25. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC, Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey-Prevot B, Root DE, Sabatini DM, Taipale J, Perrimon N, Bernards R. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006;3:777-779.
26. Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, Lee JY, Nam SW. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2013;[Epub ahead of print].
27. Moore RL, Faller DV. SIRT1 represses estrogen-signaling, ligand-independent ERalpha-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol 2013;216:273-285.
28. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, Lee H, Chung MJ, Kang MJ, Lee DG, Moon WS, Jang KY. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009;15:4453-4459.
29. Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ, Lee DG, Kim MH, Lee JH, Chung MJ. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract 2013;209:365-370.
30. Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, Deng SC, Liu Y, Liu L, Wang B, Tian K, Wang GB, Wang CY. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 2011;18:920-928.
31. Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, Nozawa Y, Deguchi T, Ito M. Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. Int J Urol 2012;19:71-79.
32. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012;31:4619-4629.
33. Sun L, Li H, Chen J, Iwasaki Y, Kubota T, Matsuoka M, Shen A, Chen Q, Xu Y. PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. J Cell Sci 2013;126:3939-47.
34. Sun L, Li H, Chen J, Dehennaut V, Zhao Y, Yang Y, Iwasaki Y, Kahn-Perles B, Leprince D, Chen Q, Shen A, Xu Y. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. J Natl Cancer Inst 2013;105:887-898.
35. Jang SH, Min KW, Paik SS, Jang KS. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol 2012;65:735-739.
36. Zhang L, Wang X, Chen P. MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer 2013;13:290.
37. Liu P, Wilson MJ. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-kappaB factor in human fibrosarcoma cells. J Cell Physiol 2012;227:867-876.
38. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011;193:409-424.